Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMP-54F28 + sorafenib
- Development stage
- Phase 1
- Lead developer
- Mereo BioPharma
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
OMP-54F28 (ipafricept) is a recombinant fusion protein that combines the cysteine-rich domain of the frizzled family receptor 8 (Fzd8) with the immunoglobulin Fc domain. It acts as a decoy receptor to antagonize Wnt signaling by competing with native Fzd8 for its ligands. Inhibition of Wnt signaling reduces tumor growth and cancer stem cell frequency. Sorafenib is an oral small molecule multikinase inhibitor that targets cell surface tyrosine kinase receptors and downstream intracellular kinases involved in tumor proliferation and angiogenesis. The combination has been studied in phase 1b clinical trials for hepatocellular carcinoma[2][3][4].
- Brand names
- Nexavar
- Other names
- OMP-54F28OMP54F28OMP 54F28ipafriceptsorafenib
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)RAF1 (c-Raf-1 (Y340D/Y341D))FGFR1 (Fibroblast growth factor receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)Wnt (Wnt ligand)RTKs (Multiple Tyrosine Kinase Receptors)
Beyond the preview
Go deeper on OMP-54F28 + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMP-54F28 + sorafenib.